StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Krystal Biotech price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Krystal Biotech's price to book ratio was 6.7× on Nov 11, 2026, against 5.6× a year earlier. Over the last 5 years it ranged from 2.5× to 8.6×, with a median of 5.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.7×+0.4
2025Dec 31, 20256.3×+1.2
2024Dec 31, 20245.1×+0.5
2023Dec 29, 20234.6×+0.9
2022Dec 30, 20223.8×−0.0
2021Dec 31, 20213.8×−0.1
2020Dec 31, 20203.9×−0.7
2019Dec 31, 20194.6×+0.3
2018Dec 31, 20184.4×+2.2
2017Dec 29, 20172.1×–

More Krystal Biotech figures

See a number that looks wrong?